ATE197053T1 - Humaner rezeptor fc(gamma)riii - Google Patents

Humaner rezeptor fc(gamma)riii

Info

Publication number
ATE197053T1
ATE197053T1 AT89305241T AT89305241T ATE197053T1 AT E197053 T1 ATE197053 T1 AT E197053T1 AT 89305241 T AT89305241 T AT 89305241T AT 89305241 T AT89305241 T AT 89305241T AT E197053 T1 ATE197053 T1 AT E197053T1
Authority
AT
Austria
Prior art keywords
riii
gamma
human receptor
variants
image
Prior art date
Application number
AT89305241T
Other languages
English (en)
Inventor
Gary A Peltz
Kevin W Moore
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE197053T1 publication Critical patent/ATE197053T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
AT89305241T 1988-05-27 1989-05-24 Humaner rezeptor fc(gamma)riii ATE197053T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19951388A 1988-05-27 1988-05-27
US30003989A 1989-01-19 1989-01-19

Publications (1)

Publication Number Publication Date
ATE197053T1 true ATE197053T1 (de) 2000-11-15

Family

ID=26894851

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97106398T ATE321134T1 (de) 1988-05-27 1989-05-24 Menschlicher fc-gamma-rezeptor iii
AT89305241T ATE197053T1 (de) 1988-05-27 1989-05-24 Humaner rezeptor fc(gamma)riii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97106398T ATE321134T1 (de) 1988-05-27 1989-05-24 Menschlicher fc-gamma-rezeptor iii

Country Status (10)

Country Link
US (2) US5976831A (de)
EP (3) EP0449828A1 (de)
JP (1) JP2657221B2 (de)
KR (1) KR0149012B1 (de)
AT (2) ATE321134T1 (de)
AU (1) AU3740089A (de)
DE (3) DE68929546D1 (de)
ES (2) ES2262163T3 (de)
GR (1) GR3034698T3 (de)
WO (1) WO1989011490A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767077A (en) * 1988-05-27 1998-06-16 Applied Research Systems Ars Holding N.V. Human Fc-γ receptor III
WO1989011490A1 (en) * 1988-05-27 1989-11-30 Schering Biotech Corporation HUMAN Fcgamma RECEPTOR III
US7038031B1 (en) * 1989-07-28 2006-05-02 Sloan-Kettering Institute For Cancer Research DNA encoding FcγR receptor protein on NK cells
FR2655269B1 (fr) * 1989-12-01 1994-02-11 Curie Universite Pierre Marie Proteines empechant l'interaction entre un fragment fc d'une immunoglobuline et son recepteur et utilisation en therapeutique, notamment dans le traitement des affections liees aux virus hiv.
FR2702481B1 (fr) * 1993-03-09 1995-04-28 Roussel Uclaf Nouveaux récepteurs Fc-gamma III humains solubles, leur procédé de préparation, les compositions pharmaceutiques les contenant, leur application comme médicaments et leur application diagnostique.
US5641875A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania DNA encoding chimeric IgG Fc receptor
WO1995014772A1 (en) * 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
US6444789B1 (en) * 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
FR2739560B1 (fr) * 1995-10-09 1997-11-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite du cd16 humain soluble dans le traitement de l'infection par le virus vih
US7468139B2 (en) 1997-07-15 2008-12-23 Silverbrook Research Pty Ltd Method of depositing heater material over a photoresist scaffold
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US7556356B1 (en) 1997-07-15 2009-07-07 Silverbrook Research Pty Ltd Inkjet printhead integrated circuit with ink spread prevention
US6712453B2 (en) 1997-07-15 2004-03-30 Silverbrook Research Pty Ltd. Ink jet nozzle rim
US7465030B2 (en) 1997-07-15 2008-12-16 Silverbrook Research Pty Ltd Nozzle arrangement with a magnetic field generator
US6648453B2 (en) 1997-07-15 2003-11-18 Silverbrook Research Pty Ltd Ink jet printhead chip with predetermined micro-electromechanical systems height
US6855264B1 (en) 1997-07-15 2005-02-15 Kia Silverbrook Method of manufacture of an ink jet printer having a thermal actuator comprising an external coil spring
US7287836B2 (en) * 1997-07-15 2007-10-30 Sil;Verbrook Research Pty Ltd Ink jet printhead with circular cross section chamber
US6935724B2 (en) 1997-07-15 2005-08-30 Silverbrook Research Pty Ltd Ink jet nozzle having actuator with anchor positioned between nozzle chamber and actuator connection point
US7195339B2 (en) 1997-07-15 2007-03-27 Silverbrook Research Pty Ltd Ink jet nozzle assembly with a thermal bend actuator
EP1006183A1 (de) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinante, lösliche Fc-Rezeptoren
DE02782887T1 (de) * 2001-10-19 2005-01-13 Centre Hospitalier Regional et Universitair de Tours Methoden und kompositionen, antikörper behandlung zu bewerten
JP4524181B2 (ja) 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
EP2368578A1 (de) 2003-01-09 2011-09-28 Macrogenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2512974A1 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
US20070190657A1 (en) * 2004-06-15 2007-08-16 Universite Francois Rabelais Methods of assessing susceptibility to drug-induced thrombocytopenia
PL2921500T3 (pl) 2004-07-10 2024-02-05 The Institute For Cancer Research Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
WO2007009469A2 (en) 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an fc receptor
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
HUE029925T2 (en) 2008-04-02 2017-04-28 Macrogenics Inc HER2 / neu-specific antibodies and methods using them
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US8883496B2 (en) 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice
NO2516457T3 (de) 2009-12-21 2018-08-11
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2492689B8 (de) * 2011-02-22 2013-12-25 Bernhard-Nocht-Institut für Tropenmedizin Nachweis von Antikörpern mit einem verbesserten Immunkomplex- (IC) ELISA
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
RU2700484C2 (ru) 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
EP3162895B1 (de) * 2014-06-27 2020-11-25 Tosoh Corporation Verbessertes fc-bindendes protein, verfahren zur herstellung dieses proteins und antikörperadsorbens mit diesem protein sowie verfahren zur antikörpertrennung unter verwendung des besagten adsorbens
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199153A (en) * 1878-01-15 Improvement in sulky-plows
ATE147432T1 (de) * 1986-05-29 1997-01-15 Ilexus Pty Ltd Polynucleotidsequenzen, die für den humanen fc- rezeptor für immunoglobulin codieren
FR2611913B1 (fr) * 1987-02-24 1994-04-15 Khayat David Procede de dosage des recepteurs fc gamma solubles seriques, coffret de dosage correspondant et applications
WO1989008114A1 (en) * 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
WO1989011490A1 (en) * 1988-05-27 1989-11-30 Schering Biotech Corporation HUMAN Fcgamma RECEPTOR III

Also Published As

Publication number Publication date
WO1989011490A1 (en) 1989-11-30
AU3740089A (en) 1989-12-12
EP0791653A1 (de) 1997-08-27
GR3034698T3 (en) 2001-01-31
EP0343950A2 (de) 1989-11-29
KR900701843A (ko) 1990-12-04
ATE321134T1 (de) 2006-04-15
EP0791653B1 (de) 2006-03-22
DE68929546D1 (de) 2006-05-11
EP0449828A1 (de) 1991-10-09
EP0343950B1 (de) 2000-10-18
EP0791653B9 (de) 2006-08-30
KR0149012B1 (ko) 1998-08-17
DE68929546T4 (de) 2007-03-08
EP0343950A3 (de) 1991-07-10
US5976831A (en) 1999-11-02
DE68929256T2 (de) 2001-05-17
DE68929546T2 (de) 2006-09-21
ES2150898T3 (es) 2000-12-16
ES2262163T3 (es) 2006-11-16
US6294347B1 (en) 2001-09-25
JPH03501484A (ja) 1991-04-04
JP2657221B2 (ja) 1997-09-24
DE68929256D1 (de) 2000-11-23
HK1001403A1 (en) 1998-06-19

Similar Documents

Publication Publication Date Title
DE68929256D1 (de) Humaner Rezeptor Fc(gamma)RIII
MY102472A (en) Preparation of funtional human urokinase proteins.
DE3789973D1 (de) Zahnimplantat zur Befestigung von Zahnersatz-Suprakonstruktionen.
NO864555D0 (no) Fremgangsmaate og fremstilling av insulinpreparat.
IL78444A (en) Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
DK228190D0 (da) Rajgraespollenallergen
EP0261224A4 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
DE3876400D1 (de) Aminosaeure-imid-derivate, ihre verwendung und diese enthaltende medizinische zusammensetzungen.
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
DK175843B1 (da) Polypeptider af overfladeaktive alvelolarproteiner (ASP), farmaceutisk sammensætning indeholdende polypeptidet, DNA-ekspressionssystem der koder for polypeptidet, samt fremgangsmåde til fremstilling af polypeptider med ASP-aktivitet
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
DE3773295D1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
FI873606A7 (fi) Ihmisen glykoalbumiinin määrittämiseen käyttökelpoisia vasta-aineita.
DK0588177T3 (da) Interferon-alpha/beta-bindende protein, fremstilling heraf samt farmaceutiske præparater indeholdende proteinet
NO881502D0 (no) Rekombinante htlv-111 proteiner og anvendelse av disse.
NO854903L (no) Peptidvaksine eller -diagnosemiddel, samt polypeptid for slik anvendelse.
PT524421E (pt) Herpesvirus humano tipo 6 proteina p 100, sequencias de adn correspondentes, preparacao e utilizacao
DK319384A (da) 1-0-alkyl-3-amino-propan-1,2-diol-2-0-phospholipider, fremgangsmaade til deres fremstilling samt farmaceutiske praeparater indeholdende disse
NO170936C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive, substituerte vinylcefalosporiner
IL86710A0 (en) Polypeptide receptor for interleukin-2,antibodies against this polypeptide and pharmaceutical compositions containing the same
GR3005231T3 (de)
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
BR6802052U (pt) Mascara cirurgica descartavel retangular com cadarcos costurados pelo sistema hrow(hight resfst one way)
DE3884149D1 (de) Elektrooptisches Abbildungssystem.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time